Medtronic Inc. SynchroMed El Implantable Infusion Pump Recall
Keywords: Lawsuit | Medtronic | Lawyer | Syncromed | Infusion | Recall | Attorney
In August 2007, Medtronic Inc. SynchroMed El Implantable Infusion Pumps were the subject of a Class I Food & Drug Administration (FDA) recall. According to the FDA recall notice posted on the agency’s website in February 2008, the Medtronic SynchroMed El Implantable Infusion Pumps stall at an unusually high rate, putting patients at risk of serious injury or even death. The FDA only issues Class I recalls when there is a reasonable probability that use of a defective medical device will cause serious injury or death.
According to the FDA, the Medtronic Inc. SynchroMed El Implantable Infusion Pump administers drugs to a specific site in the body to treat pain, spasticity (continuous muscle contraction), and cancer. The pump is implanted in the patient, either with or without a side catheter access port, catheters, and catheter accessories.
The implantable Medtronic SynchroMed EL Programmable Pump is part of the SynchroMed EL Infusion System. The Medtronic SynchroMed El Implantable Infusion Pump recall involved models 8626-10, 8626L-10, 8626-18, 8626L-18, 8627-10, 8627L-10, 8627-18, and 8627L-18. Only those models with motors manufactured before September 1999 are affected by the recall.
The Medtronic SynchroMed El Implantable Infusion Pumps can stall at a higher rate due to gear shaft wear. If a pump motor stalls, drug delivery will stop suddenly and without warning. This stoppage will result in loss of therapy, return of the patient’s symptoms, and/or symptoms of drug underinfusion or withdrawal. According to the FDA, drug withdrawal from Intrathecal Baclofen (ITB) therapy (in the patient’s spine) can cause death if not treated immediately and effectively.
According to the FDA recall notice, Medtronic notified its customers of the SynchroMed El Implantable Infusion Pump via a letter dated August 3, 2007.
Legal Help
If you or a loved one where injured as a result of a defective Medtronic SynchroMed El Implantable Infusion Pump, you have valuable legal rights. Please fill out our online form or call 1-800-LAW-INFO (1-800-529-4636) for a free case evaluation by a qualified medical device attorney.
Medtronic SynchroMed Implantable Pump Recall
Medtronic Announces Job Cuts, Restructuring
May 7, 2008
| Parker Waichman Alonso LLP
Still struggling in the wake of last year's Sprint Fidelis Defibrillator Lead recall, medical device maker Medtronic Inc. says it plans to cut 1,100 jobs worldwide as part of a restructuring plan. Medtronic's business has been hurt, not just by the Sprint Fidelis recall, but by the declining worldwide demand for implantable defibrillators, which has been shrinking since Medtronic and competitors recalled faulty products in 2005.Medtronic suspended sales of the Sprint Fidelis Leads in...
Medtronic Unit Agrees to Consent Decree
Apr 28, 2008
| Parker Waichman Alonso LLP
An agreement has been reached by a unit of Medtronic Inc. on a consent decree with the U.S. Food and Drug Administration (FDA) over quality system improvements for its external defibrillators. The agreement—which is subject to court approval—addresses concerns raised by the FDA during inspections and outlines actions Medtronic's Physio-Control subsidiary must take to resume unrestricted distribution of the portable electronic devices. Physio-control is a maker of external...
Class I Recall for Medtronic SynchroMed and IsoMed Infusion Systems
Mar 20, 2008
| Parker Waichman Alonso LLP
Medtronic Inc.'s January communication regarding problems with its SynchroMed and IsoMed infusion systems has now been deemed a Class I recall by the Food & Drug Administration (FDA). A Class I recall indicates a situation in which there is a reasonable probability that use of the product will cause injury or death. Medtronic said the classification from the FDA does not change the recommendations made to physicians in the January 2008 letter and there is no new action required of...
Medtronic Pushes for Expansion of 'Sunshine Act'
Feb 27, 2008
| Parker Waichman Alonso LLP
Medical device maker Medtronic Inc. said on Tuesday that a proposed bill aimed at curbing inappropriate relationships between companies and physicians should require all device makers to be included, not just big ones. The proposed "Sunshine Act" was introduced earlier this year by Senators Chuck Grassley and Herb Kohl and would require companies to publicly disclose—via the Internet—certain payments made to physicians for help with product development, research, and...
Medtronic Defibrillator Lawsuit Settlements Take a Toll on Profits
Feb 22, 2008
| Parker Waichman Alonso LLP
Medtronic Inc.'s profits are off sharply, in part because of problems the company has had with its defective implantable defibrillators. Medtronic's third-quarter earnings plunged 89.0% from the prior year on charges from lawsuit settlements stemming from defective defibrillators and acquisition costs.According to Forbes.com, overall sales at Medtronic jumped 12.0% to $3.4 billion, up from $3.1 billion in the third quarter of 2006, due to strong international sales. But because of...
